TrialThe Lancet. Oncology2014

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Nathan H Fowler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.